This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
About

Menu

Close

Study Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 36-month overall efficacy1L 36-month CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementDosingTherapy management
Prescribing Information 

The information on this website is based on data from adult patients with ALK-positive advanced NSCLC (anaplastic lymphoma kinase positive advanced non small cell lung cancer) treated with LORVIQUA▼(lorlatinib), produced in line with the LORVIQUA (lorlatinib) Summary of Product Characteristics.
LORVIQUA (lorlatinib) Prescribing Information click here.
▼LORVIQUA is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. Adverse event reporting information can also be found at the bottom of the page.

LORVIQUA in first-line treatment of ALK+ advanced NSCLC1

LORVIQUA was evaluated as a first-line treatment option in the CROWN study. CROWN was a global, randomised, open-label, multicentre, Phase 3 trial of LORVIQUA vs crizotinib in patients with previously untreated, ALK-positive, locally advanced or metastatic NSCLC (N=296).1,2

Crizotinib was selected for the comparator arm because it was the standard-of-care first-line treatment at the time of trial initiation.2

Studied in a broad range of patients2

Approximately 26% of patients in both the LORVIQUA and crizotinib treatment arms had brain metastases at baseline.2

Baseline demographics (ITT population, N=296)2
Scroll left to view table
Characteristic LORVIQUA
(n=149) 		Crizotinib
(n=147)
Age, years
Mean (SD)d 59.1 (±13.1) 55.6 (±13.5)
Median (IQR) 61 (51-69) 56 (45-66)
Sex, n (%)
Female 84 (56) 91 (62)
Male 65 (44) 56 (38)
Race or ethnic group, n (%)e
White 72 (48) 72 (49)
Asian 65 (44) 65 (44)
Black 0 1 (1)
Missing 12 (8) 9 (6)
Smoking status, n (%)f
Never smoked 81 (54) 94 (64)
Previous smoker 55 (37) 43 (29)
Current smoker 13 (9) 9 (6)
ECOG PS, n (%)g
0 67 (45) 57 (39)
1 79 (53) 81 (55)
2 3 (2) 9 (6)
Baseline disease characteristics (ITT population, N=296)2
Scroll left to view table
Characteristic LORVIQUA
(n=149)		 Crizotinib
(n=147)
Current stage of disease, n (%)
IIIA 1 (1) 0
IIIB 12 (8) 8 (5)
IV 135 (91) 139 (95)
Otherh 1 (1) 0
Histologic type, n (%)
Adenocarcinoma 140 (94) 140 (95)
Adenosquamous carcinoma 6 (4) 5 (3)
Large cell carcinoma 0 1 (1)
Squamous cell carcinoma 3 (2) 1 (1)
Use of previous anticancer drug therapy, n (%)i
  12 (8) 9 (6)
Previous brain radiotherapy, n (%)
  9 (6) 10 (7)
Brain metastases at baseline, n (%)
  38 (26) 40 (27)
ReferencesaTreatment for both arms was continued until disease progression or unacceptable toxicity.1bFive patients in the crizotinib group did not receive treatment but were included in the ITT population.2cObjective response (defined as complete response or partial response), as assessed by BICR.1,2dPlus-minus values are means ±SD. Percentages may not total 100 because of rounding.2eRace or ethnic group was reported by the investigator.2fSmoking status was not reported for 1 patient in the crizotinib group.2gECOG scores range from 0 to 5, with higher scores indicating greater disability.2hThe disease stage in 1 patient who had locally advanced disease at trial entry was defined according to the AJCC, v.8.0, instead of AJCC, v.7.0, as required by the protocol. This stage was therefore classified as "other."2iAccording to the protocol, previous adjuvant or neoadjuvant anticancer therapy was allowed if it had been completed more than 12 months before randomisation. One patient who had received previous chemotherapy for metastatic disease was reported as having a protocol violation.2AJCC=American Joint Committee on Cancer; ALK=anaplastic lymphoma kinase; BICR=blinded independent central review; CDx=companion diagnostic; CNS=central nervous system; DoR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; IC-DoR=intracranial duration of response; IC-ORR=intracranial objective response rate;
IC-TTP=intracranial time-to-progression; IQR=interquartile range; ITT=intention to treat; NSCLC=non-small cell lung cancer; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; RECIST=Response Evaluation Criteria in Solid Tumours; SD=standard deviation.References:

Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics. 

Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.Study Design 
LORVIQUA 1L efficacy
 Discover the data Loading
LORVIQUA 1L CNS efficacy
 See the results Loading
PP-LOR-IRL-0066 February 2024 Legal Category S1A Further information available on request

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0891. February 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0891. February 2025

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0891. February 2025